Shilpa Medicare saw the highest growth of 1.99% in patent filings in May and 2.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Shilpa Medicare‘s patent filings and grants. Buy the databook here.
Shilpa Medicare has been focused on protecting inventions in United States(US) with eight publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 67% filings and 100% grants. The United States(US), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where Shilpa Medicare is filings its patents. Among the top granted patent authorities, Shilpa Medicare has 100% of its grants in United States(US).
AbbVie and Roche could be the strongest competitors for Shilpa Medicare
Patents related to rare diseases lead Shilpa Medicare's portfolio
Shilpa Medicare has the highest number of patents in rare diseases. For rare diseases no patents were filed and 100% of patents were granted in Q2 2024.
Prostate cancer related patents lead Shilpa Medicare portfolio followed by hypertension, and becker muscular dystrophy
Shilpa Medicare has highest number of patents in prostate cancer followed by hypertension, becker muscular dystrophy, rheumatoid arthritis, and chronic obstructive pulmonary disease (copd). For prostate cancer, nearly 33% of patents were filed and 3% of patents were granted in Q2 2024.
For comprehensive analysis of Shilpa Medicare's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.